15 Dec 2017

(330 votes)

Rigvir® in Romania: Your Two-Step Guide to Learn If You Qualify For Virotherapy

Don’t get desperate if one day you discover that conventional medicine is helpless in your cancer case. Truth be told, neither chemo nor radio can guarantee the results. Even though this also relates to Rigvir®, the drug is much less harmful to your healthy cells laser focusing only on your tumor. So, let’s find out how you can get access to virotherapy in Romania.

First Clinical Trials In 1968 and Official Registration In Latvia In 2014

A few words about Rigvir® before we proceed.

The first registered medicine is Rigvir®, abbreviated from Riga virus. Rigvir® operating principle is quite simple and clear. Rigvir® is injected intramuscularly and immediately starts to troubleshoot malignant cells. The functional mode of the vaccine lies in reaching the malignant cells to eliminate them from the inside.

As the drug itself was invented in the middle of the previous century, the very first clinical trials took place in 1968. Back then, 415 melanoma patients received the treatment, and the results showed that their level of health improved [1]. Moreover, there’s clinical experience in treating other types of cancer with Rigvir®. Therefore, each case should be studied individually.

It took almost 50 years to register Rigvir® in 2004 in Latvia. Naturally, it has become the world’s most visited destination for virotherapy in patients and doctors striving to implement virotherapy back home. Latvia, however, is not the only location which officially recognized Rigvir®. Georgia did the same in 2015 while Armenia, the neighboring country, registered the drug in 2016.

Virotherapy in Romania isn’t that common yet making Rigvir® search a tough task. The drug manufacturer has recently received Horizon 2020, the biggest EU Research and Innovation programme. This means that more clinical trials are carried out with Rigvir® to introduce the drug to a wider audience.

To learn if you will benefit from Rigvir® cancer treatment, please follow the next steps:

  1. Search for your diagnosis in the left column.
  2. If found, collect the medical documents listed in the right column to apply for a free case evaluation.


As collecting the medical documentation may take a few weeks, it can be a good idea to start collecting the files as soon as possible. You’ll have to wait only 2-3 days to receive the answer from the cancer specialists whether you or the one you love qualify for the virotherapy course. Moreover, the final verdict of your admission to the treatment is oftentimes made by the Chief Oncologist of Latvia.

Virotherapy in Romania: How It Works After You Get Approved

If you get approved for Rigvir® therapy after the free case assessment, you will receive the detailed information about the following package:

For more information about other locations, read about virotherapy in the UK, virotherapy in Canada, and Rigvir in New Zealand.

We understand that at this point you may still have a lot of questions. Please click the button below and we’ll get back to you almost immediately (but not later than within the first 24 hours).




List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.

  2. “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.

  3. Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.